Abstract: ?-hydroxybutyric acid in combination with ?-hydroxybutyrate salts are useful to induce ketosis, achieving blood ketone levels of (0.5-6.0 mmol/L), with or without dietary restriction, and without inducing harmfully high mineral loads in the blood. The combination of ?-hydroxybutyric acid and salt results in substantial improvements in metabolic biomarkers related to insulin resistance, diabetes, weight loss, and physical performance & endurance in a short period of time. Further, use of these supplements to achieve ketosis yields a significant elevation of blood ketones and reduction of blood glucose levels. These acid/salt mixtures are also useful for suppressing appetite, preventing epileptic seizures, and treating cancer.
Abstract: The present invention demonstrates the therapeutic use of ketone esters for seizure disorders, Alzheimer's disease malignant brain cancer, and other cancers, which are associated with metabolic dysregulation. The administration of a ketogenic diet, such as ketone esters, while concurrently subjecting the patient to a hyperbaric, oxygen-enriched environment resulted in therapeutic ketosis. Optionally, the hyperbaric, oxygen-enriched environment is 100% oxygen at 2.5 ATA absolute. The ketone esters may be derived from acetoacetate and can include R,S-1,3-butanediol acetoacetate monoester, R,S-1,3-butanediol acetoacetate diester, or a combination of the two. The treatment may further include administering at least 10% ketone supplementation, such as acetoacetate, adenosine monophosphate kinase, 1,3-butanediol, or ketone ester, to the patient.
Type:
Application
Filed:
November 12, 2013
Publication date:
March 13, 2014
Applicants:
SAVIND, INC., UNIVERSITY OF SOUTH FLORIDA
Inventors:
Dominic Paul D'Agostino, Patrick Arnold, Angela Marie Poff
Abstract: The present invention demonstrates the therapeutic use of ketone esters for seizure disorders, Alzheimer's disease and malignant brain cancer, which are associated with metabolic dysregulation. The administration of ketone esters resulted therapeutic ketosis and neuroprotection against seizures resulting from CNS oxygen toxicity. Supplemental ketones were also found to reduce superoxide production in cultured cortex neurons exposed to hyperbaric oxygen and A?-42, and to decrease proliferation and viability in U87 glioma cells. These observations support the therapeutic effect of ketones for seizure disorders, Alzheimer's disease and malignant brain cancer. The ketone esters may be derived from acetoacetate and can include R,S-1,3-butanediol acetoacetate monoester, R,S-1,3-butanediol acetoacetate diester, or a combination of the two.
Type:
Application
Filed:
November 12, 2013
Publication date:
March 13, 2014
Applicants:
SAVIND, INC., UNIVERSITY OF SOUTH FLORIDA
Inventors:
Dominic Paul D'Agostino, Jay B. Dean, Raffaele Pilla, Patrick Arnold